Curis, Inc.

NasdaqCM:CRIS 주식 보고서

시가총액: US$40.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Curis 관리

관리 기준 확인 3/4

Curis' CEO는 Jim Dentzer, Sep2018 에 임명되었습니다 의 임기는 5.75 년입니다. 총 연간 보상은 $ 1.66M, 38.1% 로 구성됩니다. 38.1% 급여 및 61.9% 보너스(회사 주식 및 옵션 포함). 는 $ 47.45K 가치에 해당하는 회사 주식의 0.1% 직접 소유합니다. 47.45K. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 9.9 년입니다.

주요 정보

Jim Dentzer

최고 경영자

US$1.7m

총 보상

CEO 급여 비율38.1%
CEO 임기5.8yrs
CEO 소유권0.1%
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간9.9yrs

최근 관리 업데이트

Recent updates

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Nov 03
We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Apr 19
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28
Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04
Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29
We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19
Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17
Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03
What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

CEO 보상 분석

Jim Dentzer 의 보수는 Curis 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$634k

-US$47m

Sep 30 2023n/an/a

-US$47m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$3mUS$615k

-US$57m

Sep 30 2022n/an/a

-US$59m

Jun 30 2022n/an/a

-US$57m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$3mUS$590k

-US$45m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$2mUS$545k

-US$30m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$510k

-US$32m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$2mUS$479k

-US$33m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$43m

Mar 31 2018n/an/a

-US$48m

Dec 31 2017US$2mUS$443k

-US$53m

보상 대 시장: Jim 의 총 보상 ($USD 1.66M )은 US 시장( $USD 683.56K ).

보상과 수익: Jim 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Jim Dentzer (57 yo)

5.8yrs

테뉴어

US$1,662,978

보상

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...


리더십 팀

이름위치테뉴어보상소유권
James Dentzer
President5.8yrsUS$1.66m0.10%
$ 42.0k
Diantha Duvall
CFO and Principal Financial & Accounting Officer1.8yrsUS$1.01m0.011%
$ 4.4k
Jonathan Zung
Chief Development Officer1.1yrsUS$1.04m0%
$ 0
Mark Noel
Vice President of Technology Management & Intellectual Property15.8yrsUS$413.39k데이터 없음
Robert Martell
Chief Scientific Officerno dataUS$1.17m0%
$ 0
Elif McDonald
VP of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Reinhard von Roemeling
Senior Vice President of Clinical Development4.8yrs데이터 없음데이터 없음

4.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CRIS 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
James Dentzer
President5.8yrsUS$1.66m0.10%
$ 42.0k
Martyn Greenacre
Independent Chairman of the Board24.3yrsUS$158.70k0.022%
$ 9.0k
Marc Rubin
Independent Director14yrsUS$123.70k0.024%
$ 9.9k
Kenneth Kaitin
Independent Director20.6yrsUS$126.20k0.024%
$ 9.7k
John Hohneker
Independent Director2.5yrsUS$106.20k0%
$ 0
Anne Borgman-Hagey
Independent Director1.7yrsUS$103.70k0%
$ 0

9.9yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: CRIS 의 이사회경험(평균 재직 기간 9.9 년)으로 간주됩니다.